Filing summary
Period and entity: The supplied metadata identifies SS Innovations International, Inc. and 2021 Q1, but the filing itself is for Avra Medical Robotics, Inc. and the quarter and nine months ended September 30, 2021. It was signed November 3, 2022. The filing describes a possible later name change to SS Innovations, Inc. The period and issuer discrepancy should be resolved before relying on this summary.
Business context and results
Avra described itself as a development-stage medical robotics company, pursuing an AI-guided robotic system initially aimed at aesthetic skin-resurfacing procedures. It reported no revenue in either the three- or nine-month periods and was still developing its product; it had not established a revenue-generating business.
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Revenue | $0 in 2021 and 2020 | $0 in 2021 and 2020 |
| Operating expenses | $418,238 in 2021; $375,213 in 2020 | $1,130,668 in 2021; $901,872 in 2020 |
| Net loss | $418,209 in 2021; $375,526 in 2020 | $1,130,579 in 2021; $902,841 in 2020 |
| Loss per share, basic and diluted | $(0.02) in both years | $(0.04) in both years |
| Operating cash used | Not provided for the quarter | $248,414 in 2021; $84,619 in 2020 |
Gross margin and operating margin are not meaningful because the company reported no revenue.
Financial position and changes
At September 30, 2021, cash was $205,195, total assets were $334,401, current liabilities were $1,275,898, and total stockholders’ deficit was $941,496. Related-party notes payable were $145,000. Cash increased by $44,486 during the nine months, supported principally by $267,850 in securities-offering proceeds and other financing; operating activities used $248,414. The filing reports $12,150 of net cash provided by investing activities, although the cash-flow section’s labeling and presentation are unclear.
Compared with 2020, nine-month net loss increased by $227,738. Compensation expense rose to $812,381 from $680,102, and general and administrative expense increased to $317,286 from $219,770; research and development expense fell to $1,000 from $2,000. The quarterly loss also increased, with management attributing the increase largely to higher general and administrative expense. Weighted-average shares for the quarter increased to 27.7 million from 22.1 million.
During the quarter, the CEO converted $50,000 of notes and $50,000 of accrued salary into common shares, according to the notes. The company also issued shares and recorded shares issuable for services and equity offerings, contributing to dilution.
Outlook, risks, and unusual items
- Going concern and funding: Management said the company had no established revenue source sufficient to cover costs and depended on debt and equity financing. The filing states that these conditions raise substantial doubt about its ability to continue as a going concern. No committed financing source was identified; additional funding could dilute shareholders or, if unavailable, force curtailed operations or strategic alternatives.
- Development and regulatory execution: The company expected to need substantial funds for research and development, regulatory approval, manufacturing, and commercialization. It described an FDA process and product-development plans, but did not provide firm revenue or commercialization guidance.
- Controls: Management concluded disclosure controls were not effective at the reasonable-assurance level because of material weaknesses previously identified. No material change in internal control over financial reporting was reported during the period.
- Subsequent transaction disclosures: The filing discusses a non-binding August 2022 letter of intent for a business combination with SSI-related parties, potential substantial ownership dilution for existing Avra shareholders, and interim financing advanced to those parties. The proposed transaction remained conditional, with no assurance of completion. These 2022 events are subsequent to the 2021 reporting period.
- Disclosure inconsistencies: The filing’s going-concern note describes a stockholders’ deficit of $8,124,326, which matches the accumulated deficit line, while the balance sheet reports total stockholders’ deficit of $941,496. It also contains an apparent mismatch in the controls discussion between the evaluation date and the stated conclusion date.
Important facts to verify
- Confirm the issuer, intended reporting period, and whether this Avra filing is the correct filing for the requested SS Innovations International summary.
- Reconcile the going-concern deficit disclosure with the balance-sheet total stockholders’ deficit and clarify the reported cash-flow investing amount.
- Review the company’s latest cash position, financing availability, and ability to fund operations, given the stated going-concern uncertainty.
- Verify the status and final terms, if any, of the proposed SSI business combination and related convertible financing, including dilution to existing shareholders.
- Assess the material weaknesses in disclosure controls and whether they were remediated.